A REVIEW ON CD88-EXPRESSING IMMUNE CELLS AND THEIR INFLUENCE ON ATHEROSCLEROSIS

Received 2021-07-23; Accepted 2021-09-29; Published 2022-12-31

Authors

  • Muhammad Hayatuddeen Rumah Department of Microbiology, Faculty of Natural and Applied Sciences, Umaru Musa Yar adua University, Katsina, Dutsinma Road, P.M.B..,2218, Katsina, Katsina State, Nigeria
  • Ida Shazrina Ismail Department of Biomedical Sciences, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Bertam, 13200 Kepala Batas, Pulau Pinang, Malaysia
  • Rafeezul Mohamed Department of Biomedical Sciences, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Bertam, 13200 Kepala Batas, Pulau Pinang, Malaysia
  • Muhammad Amir Yunus Department of Biomedical Sciences, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Bertam, 13200 Kepala Batas, Pulau Pinang, Malaysia

DOI:

https://doi.org/10.22452/jummec.sp2022no1.11

Abstract

CD88, which stands for "Cluster of Differentiation 88," is also known as C5aR, which stands for "Complement 5a receptor." This complement receptor has 7 transmembrane domains and is found on various cell types, including monocytes, macrophages, dendritic cells, epithelial cells, adipocytes, and endothelial cells. Atherosclerosis is a condition associated with chronic inflammation of the arterial walls. It's marked by lipid retention and building, monocyte and T lymphocyte recruitment into the intima, foam cell generation, smooth muscle cell proliferation, and collagen and protein accumulation. C5a has been found in a wide range of atherosclerotic lesions, from fatty streaks to advanced plaques. The expression of CD88 has been linked to both proatherogenic and antiatherogenic effects in atherosclerosis. Initial activities of C5a in atherosclerosis include chemotaxis, oxidative burst, and vascular adhesion molecule activation. CD88 expression has also been linked to the formation of atherosclerosis plaques via adaptive immune cell activation. Regulation and effector functions require ligand-receptor binding (C5a-C5aR) in the pathogenesis of atherosclerosis. CD88 expression has been linked to all stages of atherosclerosis. Myeloid cells have been identified to express CD88, which is responsible for many of C5a's biological properties. During atherogenesis, macrophages and dendritic cells are two important antigen presentation cells (APCs) that carry and display the CD88 surface marker. The proliferation and division of CD4+ T helper cells are controlled by macrophages, dendritic cells, and mast cells, which are also responsible for the release of both proatherogenic and antiatherogenic cytokines. However, there is no evidence that naive CD4+ T helper cells express CD88 from any of the research that has been done. Since CD88 is expressed by a wide variety of immune cells in atherosclerotic plaques, including macrophages, dendritic cells, T lymphocytes, and B lymphocytes, this review will focus on the influence of CD88 expressing immune cells in atherosclerosis formation.

Downloads

Download data is not yet available.
Globally, the prevalence of both communicable and non-communicable diseases has reached pandemic levels. The prevalence of diseases including type 2 diabetes, hypertension, and obesity is worldwide. With the help of technology, many of the most severe infectious diseases of the 20th century may now be fought. These disorders are conditions that develop over an extended period of time as a result of a combination of genetic, physiological, environmental, and behavioural factors, especially the non-communicable diseases. The goal of this Special Issue, "Combating disease: Current trends, risk, treatment and prevention" is to discuss a wide range of disease-related topics, including make studies about the current pandemic season public. We specially encourage articles that offer fresh perspectives on medicine, medical systems, and management including epidemiological studies, basic science of local and systemic responses related to the medical sciences, fundamental research in medical sciences in lowering risk, improving treatment and prevention. All Special issues of JUMMEC follow the exact peer review process as regular papers and are published along with the regular issues of the journal when they are accepted. There are additionally labelled as belonging to a Special Issue and share a particular topic of interest to the scientific community.

Downloads

Published

2022-12-31

Issue

Special Issue 1 (2022) Combating disease: Current trends, risk, treatment and prevention

Section

Research article

License

All authors agree that the article, if editorially accepted for publication, shall be licensed under the Creative Commons Attribution License 4.0 to allow others to freely access, copy and use research provided the author is correctly attributed, unless otherwise stated. All articles are available online without charge or other barriers to access. However, anyone wishing to reproduce large quantities of an article (250+) should inform the publisher. Any opinion expressed in the articles are those of the authors and do not reflect that of the University of Malaya, 50603 Kuala Lumpur, Malaysia.